Theravance Biopharma, Inc. (TBPH)

Import this data to Google Sheets with:

=jivedata("TBPH","financials")

Full statements spill as a table. For one cell: =jivedata("TBPH","Revenue") or =jivedata("TBPH","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Theravance Biopharma, Inc.

TBPH • CIK 0001583107

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-56,035	$-46,949	$-3,602	$-4,203
InterestExpenseNonoperating	—	$2,546	$2,461	$2,461
Other Nonoperating Income (Expense)	$9,116	$4,881	$10,173	$14,276
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-49,269	$-44,614	$129,247	$58,918
Income Tax Expense (Benefit)	$5,924	$11,804	$23,352	$5,110
Net Income (Loss) Attributable to Parent	$-55,193	$-56,418	$105,895	$53,808
Revenue from Contract with Customer, Excluding Assessed Tax	$57,424	$64,381	$107,464	$104,311
Research and Development Expense	$40,621	$37,643	$37,414	$26,013
Selling, General and Administrative Expense	$70,095	$69,174	$73,652	$68,748
Asset Impairment Charges	—	$0	$0	$0
Operating Expenses	$113,459	$111,330	$111,066	$108,514
Weighted Average Number of Shares Outstanding, Basic	55,303,000	48,847,000	50,317,000	51,848,000
Weighted Average Number of Shares Outstanding, Diluted	55,303,000	48,847,000	51,507,000	52,296,000
Share-based Payment Arrangement, Expense	$25,371	$21,393	$18,476	$19,550

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$39,545	$37,797	$167,806	$219,766
Debt Securities, Available-for-sale, Current	$62,881	$50,553	$147,551	$167,891
Debt Securities, Available-for-sale, Noncurrent	—	—	$11,128	$11,128
Property, Plant and Equipment, Net	$9,068	$7,418	$5,895	$5,169
Operating Lease, Right-of-Use Asset	$36,287	$28,354	$24,371	$21,926
Other Prepaid Expense, Current	$11,603	$4,204	$7,564	$8,624
Assets, Current	$133,541	$161,067	$418,460	$416,662
Restricted Cash, Noncurrent	$836	$836	$836	$836
Other Assets, Noncurrent	$8,067	$12,286	$24,880	$25,177
Assets	$381,999	$354,161	$485,570	$469,770
Operating Lease, Liability, Noncurrent	$45,236	$39,108	$31,758	$27,774
Other Liabilities, Noncurrent	$5,919	$1,890	$313	$244
Accounts Payable, Current	$1,524	$2,242	$2,568	$652
Employee-related Liabilities, Current	$6,443	$7,019	$12,592	$7,825
Operating Lease, Liability, Current	$3,923	$10,712	$10,945	$10,795
Accrued Income Taxes, Current	—	$5,853	$5,287	$5,287
Other Accrued Liabilities, Current	$1,241	$2,214	$1,485	$283
Liabilities, Current	$24,767	$32,085	$38,302	$30,766
Common Stock, Value, Issued	$1	—	$1	$1
Additional Paid in Capital	$1,122,164	$1,141,060	$1,156,288	$1,160,238
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-65	$7	$61	$-76
Retained Earnings (Accumulated Deficit)	$-909,104	$-965,522	$-859,627	$-870,458
Stockholders' Equity Attributable to Parent	$212,995	$175,545	$296,723	$289,705
Preferred Stock, Shares Authorized	230,000	230,000	230,000	230,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	48,091,000	49,471,000	51,069,000	51,891,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	—	—	$105,895	$53,808
Net Cash Provided by (Used in) Operating Activities	$-26,997	$-11,535	$238,541	$53,742
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-258,627	$-1,748	$130,009	$-62,161
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$40,381	$38,633	$168,642	$346,129
Other Depreciation and Amortization	$2,001	$1,710	$1,626	$1,552
Payments to Acquire Productive Assets	$2,488	$332	$42	$42
Payments to Acquire Debt Securities, Available-for-sale	$134,534	$140,743	$248,217	$334,981
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$31,435	$139,813	$142,975	$227,521
Share-based Payment Arrangement, Noncash Expense	$25,371	$21,393	$18,476	$19,550
Gain (Loss) on Disposition of Property Plant Equipment	$-1,352	$-34	$-35	$-35
Proceeds from Sale, Maturity and Collection of Short-term Investments	$71,377	$15,838	$15,838	$15,838
Asset Impairment Charges	—	$0	$0	$0
Net Cash Provided by (Used in) Investing Activities	$-32,697	$12,284	$-105,284	$-107,468
Operating Lease, Right-of-Use Asset, Amortization Expense	$4,152	$4,414	$4,015	$4,241
Deferred Income Taxes and Tax Credits	—	—	$-11,519	$-2,193
Other Noncash Income (Expense)	—	—	$89	$-52
Payments for Repurchase of Common Stock	$197,051	$445	$445	$445
Proceeds from Issuance of Common Stock	—	$99	$20	$20
Proceeds from Stock Plans	$618	$508	$508	$508
Proceeds from Stock Options Exercised	—	—	$766	$766
Payment, Tax Withholding, Share-based Payment Arrangement	$2,500	$2,659	$4,034	$10,579
Net Cash Provided by (Used in) Financing Activities	$-198,933	$-2,497	$-3,248	$-8,435
Income Taxes Paid, Net	$24	$109	$27,884	$24,551
Increase (Decrease) in Prepaid Expenses, Other	$3,921	$-7,399	$3,360	$1,579
Increase (Decrease) in Other Operating Assets	$1,233	$-411	$1,077	$-1,194
Increase (Decrease) in Accounts Payable	$6	$750	$326	$-1,023
Increase (Decrease) in Accrued Liabilities	$-7,095	$1,468	$4,009	$2,148
IncreaseDecreaseInOperatingLeaseLiability	$-3,001	$661	$-7,117	$-7,888
Increase (Decrease) in Other Noncurrent Liabilities	$7,547	$-532	$67	$-71

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("TBPH","financials")

Full statements spill as a table. For one cell: =jivedata("TBPH","Revenue") or =jivedata("TBPH","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.